Atherosclerosis and Cardiovascular Diseases in Progeroid Syndromes

• Kato Hisaya

  Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital

• Maezawa Yoshiro

  Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital

Abstract

Hutchinson–Gilford progeria syndrome (HGPS) and Werner syndrome (WS) are two of the representative genetic progeroid syndromes and have been widely studied in the field of aging research. HGPS is a pediatric disease in which premature aging symptoms appear in early childhood, and death occurs at an average age of 14.5 years, mainly due to cardiovascular disease (CVD). Conversely, WS patients exhibit accelerated aging phenotypes after puberty and die in their 50s due to CVD and malignant tumors. Both diseases are models of human aging, leading to a better understanding of the aging-associated development of CVD. In this review, we discuss the pathogenesis and treatment of atherosclerotic diseases presented by both progeroid syndromes with the latest findings.

Journal

• Journal of Atherosclerosis and Thrombosis

  Journal of Atherosclerosis and Thrombosis 29 (4), 439-447, 2022-04-01

  Japan Atherosclerosis Society

Keywords

• Hutchinson–Gilford progeria syndrome
• Werner syndrome
• Atherosclerosis
• Cardiovascular disease
• Aging

Details

• CRID: 1390573242799973504
• NII Article ID: 130008086716
• DOI: 10.5551/jat.rv17061
• ISSN: 18803873
• ISSN: 13403478
• PubMed: 34511576
• Web Site: https://www.jstage.jst.go.jp/article/jat/29/4/29_RV17061/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2023102954
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed